[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible), secondary U. The stem's 'rare anatomical variant' is critically underspecified—without knowing if this is portal vein thrombosis, hepatic vein anomaly, or other, we cannot determine whether TIPS is absolutely contraindicated versus technically challenging. In a hemodynamically unstable cirrhotic with refractory variceal hemorrhage, balloon tamponade (B) is the guideline-endorsed immediate bridge therapy per AASLD when TIPS is not feasible. Angiographic embolization (E) of the coronary (left gastric) vein is not standard rescue therapy for esophageal varices; it is technically difficult, not widely available, and lacks robust outcome data. While E could be considered in specialized centers, B remains the most universally appropriate next step. The keyed answer E is therefore not uniquely defensible and misrepresents management hierarchy. Medical accuracy is compromised by outdated terminology and incorrect prioritization of interventions. Minimal fix: Specify the variant (e.g., complete portal vein thrombosis) and change key to B, or revise options to include only definitive therapies after balloon tamponade.\",\"medical_accuracy_score\":   \"2\",\"logical_validity\": false,\"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible), secondary U. The stem's 'rare anatomical variant' is critically underspecified—without knowing if this is portal vein thrombosis, hepatic vein anomaly, or other, we cannot determine whether TIPS is absolutely contraindicated versus technically challenging. In a hemodynamically unstable cirrhotic with refractory variceal hemorrhage, balloon tamponade (B) is the guideline-endorsed immediate bridge therapy per AASLD when TIPS is not feasible. Angiographic embolization (E) of the coronary (left gastric) vein is not standard rescue therapy for esophageal varices; it is technically difficult, not widely available, and lacks robust outcome data. While E could be considered in specialized centers, B remains the most universally appropriate next step. The keyed answer E is therefore not uniquely defensible and misrepresents management hierarchy. Medical accuracy is compromised by outdated terminology and incorrect prioritization of interventions. Minimal fix: Specify the variant (e.g., complete portal vein thrombosis) and change key to B, or revise options to include only definitive therapies after balloon tamponade.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (Valid). Verdict: The keyed answer B (Tumor microembolism syndrome) is the unique best choice. Key discriminating clues are acute dyspnea with hypoxemia in a patient with metastatic breast cancer, a negative CT pulmonary angiogram that excludes macroscopic pulmonary embolism, and echocardiographic right ventricular strain indicating acute pulmonary vascular obstruction. Bone marrow infiltration confirms high tumor burden, a known risk factor for tumor microemboli. Alternative options are inconsistent: paclitaxel‑induced pneumonitis would produce interstitial infiltrates and lacks RV strain; lymphangitic carcinomatosis is usually subacute with characteristic CT septal thickening; chemotherapy‑associated pulmonary veno‑occlusive disease is rare with paclitaxel and presents chronically; metastatic tumor thrombus would be visible on CT angiography. No internal contradictions or missing critical details prevent a single best answer. Medical accuracy: Tumor microembolism syndrome is a well‑documented complication of adenocarcinomas, and is recognized in major oncology guidelines, and the vignette mirrors its classic presentation. The item is fully accurate, board‑relevant, and requires no revision.\",\n\"medical_accuracy_score\":  \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: The keyed answer B (Tumor microembolism syndrome) is the unique best choice. Key discriminating clues are acute dyspnea with hypoxemia in a patient with metastatic breast cancer, a negative CT pulmonary angiogram that excludes macroscopic pulmonary embolism, and echocardiographic right ventricular strain indicating acute pulmonary vascular obstruction. Bone marrow infiltration confirms high tumor burden, a known risk factor for tumor microemboli. Alternative options are inconsistent: paclitaxel‑induced pneumonitis would produce interstitial infiltrates and lacks RV strain; lymphangitic carcinomatosis is usually subacute with characteristic CT septal thickening; chemotherapy‑associated pulmonary veno‑occlusive disease is rare with paclitaxel and presents chronically; metastatic tumor thrombus would be visible on CT angiography. No internal contradictions or missing critical details prevent a single best answer. Medical accuracy: Tumor microembolism syndrome is a well‑documented complication of adenocarcinomas, and is recognized in major oncology guidelines, and the vignette mirrors its classic presentation. The item is fully accurate, board‑relevant, and requires no revision.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. The vignette presents classic aseptic meningitis (lymphocytic pleocytosis, normal glucose) in a young adult with hiking exposure, negative HSV PCR, and positive serology for a rare pathogen, establishing a diagnosis of arboviral meningitis without specific antiviral therapy. Supportive care is the unambiguous best answer. Key discriminating clues include normal CSF glucose (ruling out bacterial meningitis), negative viral PCR (excluding HSV encephalitis), and confirmed rare pathogen where only symptomatic treatment exists. Alternative options are clearly inferior: acyclovir is unnecessary without encephalitis signs; antibiotics are contraindicated by the aseptic CSF profile; corticosteroids lack evidence in viral meningitis; antifungals are unsupported by epidemiology and CSF findings. No internal contradictions exist, and only one option is defensible. Medical accuracy is high: CSF interpretation and management align with current infectious disease guidelines for viral meningitis. The only minor limitation is ambiguous timing of serology results, but this does not impact answer selection. Score: 5. Minimal fix: Replace 'initial management' with 'definitive management' to clarify the diagnostic timeline.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. The vignette presents classic aseptic meningitis (lymphocytic pleocytosis, normal glucose) in a young adult with hiking exposure, negative HSV PCR, and positive serology for a rare pathogen, establishing a diagnosis of arboviral meningitis without specific antiviral therapy. Supportive care is the unambiguous best answer. Key discriminating clues include normal CSF glucose (ruling out bacterial meningitis), negative viral PCR (excluding HSV encephalitis), and confirmed rare pathogen where only symptomatic treatment exists. Alternative options are clearly inferior: acyclovir is unnecessary without encephalitis signs; antibiotics are contraindicated by the aseptic CSF profile; corticosteroids lack evidence in viral meningitis; antifungals are unsupported by epidemiology and CSF findings. No internal contradictions exist, and only one option is defensible. Medical accuracy is high: CSF interpretation and management align with current infectious disease guidelines for viral meningitis. The only minor limitation is ambiguous timing of serology results, but this does not impact answer selection. Score: 5. Minimal fix: Replace 'initial management' with 'definitive management' to clarify the diagnostic timeline.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible). Verdict: The keyed answer (B) is not uniquely determinable as the single best first-line therapy. Key stem clues—autism, multifocal epileptiform discharges, cortical dysplasia, de novo mutation—suggest a broad-spectrum AED is appropriate. Both valproic acid (A) and levetiracetam (B) are reasonable first-line options; the stem provides no discriminating information (e.g., specific gene, prior behavioral adverse events) to prefer one over the other. Carbamazepine (C) is less suitable for multifocal disease, and VNS (D) and ketogenic diet (E) are not first-line. The rationale’s claim that levetiracetam is preferred for SCN8A-related encephalopathy is inaccurate; sodium channel blockers are typically first-line for SCN8A. This factual error undermines the key’s defensibility. Logical issue: underspecification leads to two equally plausible answers, making the item ambiguous. Medical accuracy: minor but significant inaccuracy regarding genotype‑treatment pairing. Minimal fix: specify the mutation (e.g., SCN8A) and include a clue about behavioral side‑effect profile (e.g., prior aggression on valproic acid) to justify levetiracetam as the unique best choice.\",\n\"medical_accuracy_score\":   \t\"3\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible). Verdict: The keyed answer (B) is not uniquely determinable as the single best first-line therapy. Key stem clues—autism, multifocal epileptiform discharges, cortical dysplasia, de novo mutation—suggest a broad-spectrum AED is appropriate. Both valproic acid (A) and levetiracetam (B) are reasonable first-line options; the stem provides no discriminating information (e.g., specific gene, prior behavioral adverse events) to prefer one over the other. Carbamazepine (C) is less suitable for multifocal disease, and VNS (D) and ketogenic diet (E) are not first-line. The rationale’s claim that levetiracetam is preferred for SCN8A-related encephalopathy is inaccurate; sodium channel blockers are typically first-line for SCN8A. This factual error undermines the key’s defensibility. Logical issue: underspecification leads to two equally plausible answers, making the item ambiguous. Medical accuracy: minor but significant inaccuracy regarding genotype‑treatment pairing. Minimal fix: specify the mutation (e.g., SCN8A) and include a clue about behavioral side‑effect profile (e.g., prior aggression on valproic acid) to justify levetiracetam as the unique best choice.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V (Valid). Verdict: Correct best answer. Key stem clues driving the answer are: (1) lenticulostriate territory infarction (small vessel location), (2) normal vessel imaging (rules out large-vessel occlusion and visible vasculitis), and (3) abnormal coagulation studies (points toward hematologic etiology). The combination of a small-vessel territory infarct with documented coagulopathy makes antiphospholipid syndrome (APS) the only option that explains both findings. Lacunar infarct (B) fits the location but cannot account for the coagulation abnormality. Cardioembolism (A, E) is unlikely in this isolated small-vessel territory without evidence of arrhythmia. Vasculitis (D) is inconsistent with normal vessel imaging. No internal contradictions exist, and the key is supported. Main medical accuracy issues: (1) Rationale incorrectly states lacunar infarcts are \\\"not matching this profile\\\" when lenticulostriate is the classic location; (2) Parkinson's disease is irrelevant and distracting; (3) \\\"Coagulation studies abnormal\\\" is vague—specificity matters (e.g., lupus anticoagulant vs. nonspecific D-dimer). Minimal fix: Specify \\\"lupus anticoagulant positive\\\" in stem, remove Parkinson's disease, and revise rationale to state: \\\"While lacunar infarct is most common in this location, the documented hypercoagulability makes APS the best answer.\\\"\",\"medical_accuracy_score\":   \"3\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: Correct best answer. Key stem clues driving the answer are: (1) lenticulostriate territory infarction (small vessel location), (2) normal vessel imaging (rules out large-vessel occlusion and visible vasculitis), and (3) abnormal coagulation studies (points toward hematologic etiology). The combination of a small-vessel territory infarct with documented coagulopathy makes antiphospholipid syndrome (APS) the only option that explains both findings. Lacunar infarct (B) fits the location but cannot account for the coagulation abnormality. Cardioembolism (A, E) is unlikely in this isolated small-vessel territory without evidence of arrhythmia. Vasculitis (D) is inconsistent with normal vessel imaging. No internal contradictions exist, and the key is supported. Main medical accuracy issues: (1) Rationale incorrectly states lacunar infarcts are \"not matching this profile\" when lenticulostriate is the classic location; (2) Parkinson's disease is irrelevant and distracting; (3) \"Coagulation studies abnormal\" is vague—specificity matters (e.g., lupus anticoagulant vs. nonspecific D-dimer). Minimal fix: Specify \"lupus anticoagulant positive\" in stem, remove Parkinson's disease, and revise rationale to state: \"While lacunar infarct is most common in this location, the documented hypercoagulability makes APS the best answer.\"", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer D is not the best choice; A is more appropriate. The stem describes refractory septic shock with a blunted cortisol response after cosyntropin testing, indicating relative adrenal insufficiency. Current Surviving Sepsis guidelines (2021) recommend IV hydrocortisone 200 mg/day for refractory shock regardless of baseline cortisol, making A the evidence-based next step. The answer key’s rationale that steroids are ineffective when random cortisol is normal misinterprets the guidelines; hydrocortisone is not reserved for absolute deficiency. Option D (switch to vasopressin) is also a reasonable adjunct, but guidelines suggest adding vasopressin to norepinephrine rather than switching, and steroids are a higher-priority intervention in refractory shock. The stem does not specify the current vasopressor regimen, introducing ambiguity (U), but the primary flaw is the miskey. Minimal fix: Change the key to A and revise the explanation to state that hydrocortisone is indicated for refractory septic shock without requiring a cosyntropin test; optionally clarify that vasopressin is added, not switched.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer D is not the best choice; A is more appropriate. The stem describes refractory septic shock with a blunted cortisol response after cosyntropin testing, indicating relative adrenal insufficiency. Current Surviving Sepsis guidelines (2021) recommend IV hydrocortisone 200 mg/day for refractory shock regardless of baseline cortisol, making A the evidence-based next step. The answer key’s rationale that steroids are ineffective when random cortisol is normal misinterprets the guidelines; hydrocortisone is not reserved for absolute deficiency. Option D (switch to vasopressin) is also a reasonable adjunct, but guidelines suggest adding vasopressin to norepinephrine rather than switching, and steroids are a higher-priority intervention in refractory shock. The stem does not specify the current vasopressor regimen, introducing ambiguity (U), but the primary flaw is the miskey. Minimal fix: Change the key to A and revise the explanation to state that hydrocortisone is indicated for refractory septic shock without requiring a cosyntropin test; optionally clarify that vasopressin is added, not switched.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: U (Underspecified). Verdict: Not uniquely determinable. The stem describes a dasatinib-treated CML patient with pleural effusions and 'additional clonal evolution' but omits critical BCR-ABL mutation analysis. While the keyed answer C (ponatinib) is appropriate for T315I-mutated disease, clonal evolution encompasses various chromosomal abnormalities that may warrant allogeneic transplant (E) or alternative TKIs. Key discriminating clues—pleural effusion suggesting dasatinib toxicity and cytogenetic evolution implying resistance—create competing priorities: dose reduction (D) addresses toxicity, while transplant (E) is guideline-recommended for clonal evolution regardless of mutation status. The logical failure requires assuming an unstated T315I mutation to render C uniquely best. Medical accuracy issue: NCCN guidelines list clonal evolution as an indication for transplant evaluation, making E arguably superior; moreover, standard-of-care mandates mutation testing before selecting ponatinib. The explanation misrepresents transplant timing and overstates T315I frequency in clonal evolution. Minimal fix: Specify 'BCR-ABL kinase domain sequencing identifies T315I mutation' in the stem.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\": false,\"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: U (Underspecified). Verdict: Not uniquely determinable. The stem describes a dasatinib-treated CML patient with pleural effusions and 'additional clonal evolution' but omits critical BCR-ABL mutation analysis. While the keyed answer C (ponatinib) is appropriate for T315I-mutated disease, clonal evolution encompasses various chromosomal abnormalities that may warrant allogeneic transplant (E) or alternative TKIs. Key discriminating clues—pleural effusion suggesting dasatinib toxicity and cytogenetic evolution implying resistance—create competing priorities: dose reduction (D) addresses toxicity, while transplant (E) is guideline-recommended for clonal evolution regardless of mutation status. The logical failure requires assuming an unstated T315I mutation to render C uniquely best. Medical accuracy issue: NCCN guidelines list clonal evolution as an indication for transplant evaluation, making E arguably superior; moreover, standard-of-care mandates mutation testing before selecting ponatinib. The explanation misrepresents transplant timing and overstates T315I frequency in clonal evolution. Minimal fix: Specify 'BCR-ABL kinase domain sequencing identifies T315I mutation' in the stem.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem presents a classic cholinergic toxidrome (bradycardia, hypotension, miosis) with partial atropine response and symptom recurrence, pathognomonic for organophosphate poisoning. Pralidoxime (A) is the definitive antidote that reactivates acetylcholinesterase; atropine alone only temporarily masks muscarinic symptoms and cannot prevent recurrent toxicity. Alternative antidotes are clearly incorrect: N-acetylcysteine (B) treats acetaminophen toxicity lacking cholinergic signs; flumazenil (C) reverses benzodiazepines causing sedation without miosis; physostigmine (D) would worsen cholinergic crisis by increasing acetylcholine; hydroxocobalamin (E) treats cyanide poisoning with different features. No internal contradictions exist, and the clinical pattern uniquely selects pralidoxime. Medical accuracy is excellent: the mechanism, treatment hierarchy, and distractors align with current toxicology guidelines. The vignette is sufficiently specified—mentioning SLUDGE symptoms is unnecessary when core cholinergic signs plus atropine failure are present. The question appropriately tests recognition of organophosphate poisoning and the need for oxime therapy. Minimal fix: None required; item is board-ready as written.\",\"medical_accuracy_score\":  \"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem presents a classic cholinergic toxidrome (bradycardia, hypotension, miosis) with partial atropine response and symptom recurrence, pathognomonic for organophosphate poisoning. Pralidoxime (A) is the definitive antidote that reactivates acetylcholinesterase; atropine alone only temporarily masks muscarinic symptoms and cannot prevent recurrent toxicity. Alternative antidotes are clearly incorrect: N-acetylcysteine (B) treats acetaminophen toxicity lacking cholinergic signs; flumazenil (C) reverses benzodiazepines causing sedation without miosis; physostigmine (D) would worsen cholinergic crisis by increasing acetylcholine; hydroxocobalamin (E) treats cyanide poisoning with different features. No internal contradictions exist, and the clinical pattern uniquely selects pralidoxime. Medical accuracy is excellent: the mechanism, treatment hierarchy, and distractors align with current toxicology guidelines. The vignette is sufficiently specified—mentioning SLUDGE symptoms is unnecessary when core cholinergic signs plus atropine failure are present. The question appropriately tests recognition of organophosphate poisoning and the need for oxime therapy. Minimal fix: None required; item is board-ready as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (valid). Verdict: The keyed answer (E) is the correct best answer. Key stem clues: 12‑year‑old with juvenile idiopathic arthritis on etanercept, new fever/rash/lymphadenopathy, serology positive for a virus, and lymph‑node biopsy showing a clonal T‑cell population. These findings point to a T‑cell lymphoma as the most likely complication of TNF‑inhibitor therapy. Alternative options are less plausible: DRESS lacks eosinophilia and clonality; EBV‑LPD is typically B‑cell; MAS/HLH are cytokine‑driven without clonality. Thus E is uniquely defensible. Medical accuracy: The explanation correctly links TNF inhibitors to increased lymphoma risk, but it overstates the specificity for T‑cell lymphomas (most are B‑cell). Nonetheless, the presence of clonal T‑cells is a valid discriminator, and the scenario aligns with FDA warnings. Minor nuance issue does not undermine the item. Logical issue: None; the stem provides sufficient discrimination. Minimal fix: Specify the virus (e.g., EBV) and clarify that EBV‑LPD is usually B‑cell, or adjust the explanation to state that TNF inhibitors increase lymphoma risk in general and that clonal T‑cells indicate a T‑cell lymphoma.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (valid). Verdict: The keyed answer (E) is the correct best answer. Key stem clues: 12‑year‑old with juvenile idiopathic arthritis on etanercept, new fever/rash/lymphadenopathy, serology positive for a virus, and lymph‑node biopsy showing a clonal T‑cell population. These findings point to a T‑cell lymphoma as the most likely complication of TNF‑inhibitor therapy. Alternative options are less plausible: DRESS lacks eosinophilia and clonality; EBV‑LPD is typically B‑cell; MAS/HLH are cytokine‑driven without clonality. Thus E is uniquely defensible. Medical accuracy: The explanation correctly links TNF inhibitors to increased lymphoma risk, but it overstates the specificity for T‑cell lymphomas (most are B‑cell). Nonetheless, the presence of clonal T‑cells is a valid discriminator, and the scenario aligns with FDA warnings. Minor nuance issue does not undermine the item. Logical issue: None; the stem provides sufficient discrimination. Minimal fix: Specify the virus (e.g., EBV) and clarify that EBV‑LPD is usually B‑cell, or adjust the explanation to state that TNF inhibitors increase lymphoma risk in general and that clonal T‑cells indicate a T‑cell lymphoma.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). The keyed answer B is medically incorrect and dangerous. In ALS with progressive dysphagia and aspiration, the standard intervention is PEG placement (Option A) for enteral nutrition and aspiration risk reduction. Botulinum toxin paralyzes the cricopharyngeus muscle and is contraindicated in the setting of pharyngeal weakness—it is used for hypertonic conditions like cricopharyngeal bar, not ALS-related weakness. The rationale incorrectly states botulinum toxin 'relaxes' muscle to improve swallowing; it causes chemical denervation, which would worsen weakness. Speech therapy (D) is adjunctive but insufficient for advanced disease with aspiration. Tracheostomy (C) addresses ventilation/airway protection but not swallowing dysfunction. Edrophonium (E) is for myasthenia gravis, not ALS. The stem adequately describes advanced bulbar ALS; the answer choices are discriminating, but the key is wrong. Medical accuracy: The item teaches a dangerous, false principle. Score 1. Logical validity: False due to miskey. Fix: Change key to A and revise rationale: 'PEG provides enteral access, maintains nutrition, and reduces aspiration pneumonia risk in ALS patients with significant dysphagia, which is the standard of care.'\",\"medical_accuracy_score\":  \t\"1\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). The keyed answer B is medically incorrect and dangerous. In ALS with progressive dysphagia and aspiration, the standard intervention is PEG placement (Option A) for enteral nutrition and aspiration risk reduction. Botulinum toxin paralyzes the cricopharyngeus muscle and is contraindicated in the setting of pharyngeal weakness—it is used for hypertonic conditions like cricopharyngeal bar, not ALS-related weakness. The rationale incorrectly states botulinum toxin 'relaxes' muscle to improve swallowing; it causes chemical denervation, which would worsen weakness. Speech therapy (D) is adjunctive but insufficient for advanced disease with aspiration. Tracheostomy (C) addresses ventilation/airway protection but not swallowing dysfunction. Edrophonium (E) is for myasthenia gravis, not ALS. The stem adequately describes advanced bulbar ALS; the answer choices are discriminating, but the key is wrong. Medical accuracy: The item teaches a dangerous, false principle. Score 1. Logical validity: False due to miskey. Fix: Change key to A and revise rationale: 'PEG provides enteral access, maintains nutrition, and reduces aspiration pneumonia risk in ALS patients with significant dysphagia, which is the standard of care.'", "medical_accuracy_score": 1, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 1}]